Iaso Bio and Saiqiao Bio Announce Global Strategic Partnership to Advance Integrated Overseas Expansion of China's Cell Therapy Industry Chain

Sep 09, 2025 17:37 CST Updated 17:37

IASO Biotechnology

Cancer Treatment New Drug Developer

On September 9, IASO Bio and Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd. officially signed a global strategic cooperation agreement.Jointly Promote the Integrated Overseas Expansion of China-Produced Advanced Cell Therapy Drug Industry ChainZhang Jinhua, founder, chairman and CEO of IASO Bio, and Dr. Shang Yuanfang, founder, chairman and CEO of Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd., jointly attended the signing ceremony.

Group photo at the signing ceremony (Front row, left: Hua Zhang, Chief Business Officer of IASO Bio; right: Jing Chen, President of the Immune Cell Business Line at Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd.; Back row, fourth from left: Jinhua Zhang, Founder, Chairman, and CEO of IASO Bio; fourth from right: Dr. Yuanfang Shang, Founder, Chairman, and CEO of Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd., along with representatives of both management teams)

As a leading company in the field of cell therapy, IASO Bio has the full-process capability from early drug discovery, clinical development, CMC development, regulatory submission to commercialization. To benefit more patients worldwide as soon as possible, IASO Bio is actively exploring diverse cooperation models with international partners in various fields through innovation and diversity, committed to delivering advanced therapeutic solutions in forms that best align with local policies and market conditions. In addition to accelerating the drug registration and market access processes in multiple countries and regions, promoting different raw materials, processes, technologies, and services in the cell therapy industry to "go global" as a package has also become a new avenue for collaboration.

The strategic cooperation reached with Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd. this time marks the official launch of "IASO Bio Cell Production Process + Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd. Intelligent Manufacturing"The global collaboration model accelerates the integrated output of China-produced cell therapy industry chains to meet the international market's demand for advanced treatment technologies. The cooperation will be deeply advanced in two dimensions: technology synergy and market expansion. At the technical level, both parties will jointly establish a process development mechanism, combining IASO Bio's extensive experience in CAR-T drug research and development with Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd.'s core capabilities in high-end equipment adaptation, to collaboratively enhance the production feasibility of cell therapy products. In terms of the market, the two parties will integrate their international channel resources to promote the implementation and application of comprehensive solutions in overseas markets."This collaboration is not only a complementary exchange of resources between two enterprises, but also provides an important practical example for the upstream and downstream synergy of China's cell therapy industry chain to expand overseas. It is expected to further enhance the influence of China's advanced treatment technologies in the global market.

About IASO Bio

IASO Bio, established in 2017, is a leading biopharmaceutical company dedicated to the research, production, and commercialization of innovative cell therapies. The company focuses on developing hematological tumor cell-based drugs as its innovative foundation while expanding into autoimmune diseases and antibody-based therapeutics. IASO Bio possesses comprehensive capabilities across the entire process from early drug discovery, clinical development, regulatory submission, to commercialization. The company has over 10 innovative drug candidates at various stages of development, including the world's first fully human CAR-T product, an anti-BCMA injectable therapy called Equecabtagene Autoleucel (brand name: Focasor).^®) was approved for marketing by the China National Medical Products Administration (NMPA) in June 2023, for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least three prior lines of therapy (including at least one proteasome inhibitor and one immunomodulatory agent). Its frontline indication for the treatment of 2-3 line multiple myeloma (MM) has entered Phase III clinical trials. In addition, Icaritin Injection has received multiple Investigational New Drug (IND) application approvals in both China and the United States for various autoimmune diseases.

Simultaneously, the dual-target (CD19/CD22) product CT120 for lymphoma is about to enter Phase II clinical trials. Another product targeting GPRC5D for the treatment of relapsed and refractory multiple myeloma, IASO118, has received IND approval in China. In addition to cell therapy products, the company's fully human anti-CD19 antibody product, IASO-782, has obtained IND approval in both China and the United States for the treatment of multiple autoimmune diseases, while continuing to explore additional indications for autoimmune conditions. The company has successively reached global commercial expansion licensing or research collaboration agreements with overseas cell therapy companies such as Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, actively exploring the development of next-generation cell therapy products. Relying on its strong management team, innovative product pipeline, in-house GMP manufacturing, and advanced clinical development capabilities, IASO Bio is committed to bringing transformative, accessible innovative therapies and the hope of a cure to patients in China and around the world.

About Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd.

Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd. was founded in March 2020 by Professor Zhang Youming, a Ph.D. from the Department of Precision Instruments at Tsinghua University and an academician of the German National Academy of Engineering. The core team, which has over 10 years of accumulated experience in instrument engineering and biotechnology, previously led major national projects on biological instruments and is the earliest professional team in China to focus on cell processing and automation equipment.

Adhering to the development vision of "making sure that no disease is too expensive to treat," Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd. focuses on the industry characteristics of the cell therapy field, such as "process as product, tools as process," and addresses core industry pain points like "unaffordable and inaccessible" solutions by deeply collaborating with industry clients. Through integrated technological innovation in processes and tools, the company is driving the transformation of cell preparation from traditional manual open modes to a new production paradigm featuring single-unit automatic closed systems, process integration, and bedside intelligence. This breakthrough has reduced the production costs of autologous cell therapies by 5-10 times and allogeneic cell therapies by dozens of times. Its core products and solutions have covered more than 10 countries globally, over 100 cell therapy pipelines, with nearly 1,000 cumulative installations. The company has successfully supported the R&D and production of China's first MSC stem cell marketed drug and multiple CAR-T marketed drugs, becoming one of the world’s top three cell therapy tool platforms covering early research, clinical trials, and commercialization stages, with full independent intellectual property rights.